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The source and possible significance of hyaluronan in the pentoneal
cavity. The levels of hyaluronan (HA) were determined in dialysate from
patients receiving CAPD. The levels found after the four hour dwell were
0.162 0.08 .tg/ml (N = 16) in non-infected fluid and 1.69 1.12 (N =
5) during peritonitis, P < 0.0025. Similarly concentrations in overnight (8
to 10 hours) dwell dialysate were 0.384 0.22 .rg/ml (N = 13) when
uninfected and 3.17 2.28 (N = 8) during peritonitis, P < 0.0002.
Following de novo catheter insertion the initial peritoneal washout yielded
HA levels of 0.0032 0.0018 jrg/ml (N = 7). In vitro human peritoneal
cells synthesized HA, 90% of which was secreted into the culture medium
(CM). By dissociative gel permeation chromatography on Sephacryl 1000
there were no significant differences in the molecular size of HA extracted
from (a) non-infected fluid, (b) infected fluid and (c), mesothelial cell
culture medium. These results indicate that the process of CAPD results
in an increase in HA levels in the peritoneal cavity. During episodes of
peritonitis these functions are further augmented. The likely source of HA
in the dialysate is the peritoneal mesothelial cells. This response may be an
initial event in wound repair.
Hyaluronan (HA) (formely called hyaluronic acid) is a high
molecular weight linear anionic polysaccharide made up of re-
peating units of -1,4-glucuronate-31-3-N-acetylglucosamine,
which is a critical component of extracellular matrices [1, 2]. This
macromolecule is involved in a number of important physico-
chemical functions including water homeostasis, via flow resis-
tance and osmotic pressure, and lubrication, through its rheologi-
cal properties [1, 3]. HA is important in several physiological and
pathological processes and is present in high concentrations in
tissues undergoing remodeling and morphogenesis where it acts
as a support for cell adhesion and locomotion. It has also been
shown to influence cell behavior, including differentiation, prolif-
eration, and aggregation, and appears to play a critical role in the
early stages of wound healing [4—6].
The introduction of sensitive assays for HA has allowed the
detection of this important molecule in several clinical conditions
[7]. In inflammatoiy diseases such as rheumatoid arthritis, psori-
atic arthropathy and systemic scleroderma, and in certain malig-
nancies, circulating levels of HA are raised [8, 9]. In these
conditions it is likely that the increased levels reflect augmented
synthesis by target cells such as fibroblasts which are stimulated by
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different cytokines [8, 10]. In liver diseases such as cirrhosis the
increase in serum HA is the result of impaired turnover [11, 12].
HA metabolism has not been extensively studied in renal
conditions. It has been reported that in patients with chronic renal
failure undergoing dialysis, HA serum levels are slightly increased,
probably due to impaired renal metabolism [13—15]. It has also
been reported that HA concentrations in serum are elevated in
patients on continuous ambulatory peritoneal dialysis (CAPD)
[15]. Consideration of the physical and biological properties of
HA suggest that it could be of importance in the maintenance of
peritoneal membrane integrity and, in particular, play a central
role in repair processes associated with peritonitis. In this study
we have used a sensitive ELISA to measure I-IA in dialysate
derived from patients receiving CAPD as a treatment for end-
stage renal failure. We report that HA is present in low amounts
in these fluids and that it is significantly raised in effluent derived
from patients with peritonitis. In addition, we present evidence
that mesothelial cells are the probable source of peritoneal HA.
Methods
Patients
The patients in this study were all treated for end-stage kidney
failure by CAPD in the Renal Unit, Royal Infirmary, Cardiff,
Wales. Their original diagnoses included glomerulonephritis,
diabetes, polycystic disease, chronic renal failure—cause not
determined—and hypertension. Twenty-nine patients were stud-
ied when free of infection and 13 during an episode of peritonitis;
three were investigated on both occasions. All were aged from 18
to 84 years. Samples of dialysate and blood were obtained from
patients who had given their informed consent. Serum samples
were also taken from 15 normal controls aged 23 to 54 for the
measurement of HA.
Samples of spent-dialysis fluid were taken from either short-
dwell (4 hr) or overnight dwell (8 to 10 hr) bags. The samples were
centrifuged at 1000 g for 10 minutes to remove debris; the clear
supernatant was then aliquoted and stored at —20°C until assayed.
Estimation of HA levels
Prior to assay all samples were digested with papain (20 .tg/ml)
in 0.2 M sodium acetate, pH 5.8 buffer, for 16 hours at 60°C. The
papain was inactivated by boiling for 30 minutes. In control
experiments boiling hyaluronan for up to 60 minutes showed no
loss of competition in the assay, and samples of enzyme boiled for
30 minutes showed no interference in the assay. HA was deter-
mined using an ELISA protocol as described by Fosang et al [7].
Time, days after antibiotic treatment
Fig. 2. HA levels in dialysate fluid from patients treated for peritonitis and
investigated over a four day period after the introduction of antibiotic therapy.
Symbols are: (0) patient 1; (0) patient 2, (0) patient 3, () patient 4,(0) patient 5. Patients 1 and 2 (4 hr dwell). Patients 3 and 4 (overnight
dwell). Patient 5 represents a case of persistent peritonitis (Candida).
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Fig. 1. Levels of hyaluronan (HA) in 4 hour and overnight dialysate fluid
from patients on CAPD. HA values are expressed as g/m1 determined in
fluid taken from patients without (A) and with (A) peritonitis.
The assay is an enzyme-linked absorbent assay which involves the
competition between HA absorbed to microtiter plates and HA in
solution for binding to the binding region of the Gi domain of
aggrecan. This material was donated by Dr. M. Bayliss, Kennedy
Institute (Hammersmith, UK). Ninety-six-well microtiter plates
(Dynatech, Billingshurst, Kent, UK) were coated with 200 l of
HA (25 .tg!ml; Sigma, UK) prepared in 20 m sodium carbonate,
pH 9.6, at room temperature for 24 hours. The plates were
washed in a buffer containing 0.123 M NaCI, 0.01 M Na2HPO4, pH
7.2, containing 0.05% Tween 20 (PBS-Tween) and then blocked
with PBS-Tween containing 1.0% (wt!vol) BSA (Sigma, Poole,
UK) for 1.5 hours at 37°C. Samples (100 pA) or standard (100 pA;
range 1 to 1000 tgIml) were added, followed by biotinylated
Gi-domain (100 i.tl; I Wml), after which the plates were incu-
bated overnight at room temperature. Blanks contained PBS!
Tween only and wells with maximum binding contained PBS!
Tween (100 pA) and biotinylated Gi (100 j.d).
To quantify the biotinylated-Gi bound to HA on the plate, 100
pA of Streptavidin-horseradish peroxidase conjugate (1 ig/ml,
Amersham mt. PLC, UK) diluted in PBS/Tween was added to
each well and incubated at 37°C for 30 minutes. The plates were
washed with PBS/Tween (x4) and developed with 2,2' Azino-bis-
[3-ethylbenzthiazoline-6-sulphonic acid] (ABTS, Sigma) in 0.15 M
phosphate-citrate buffer, pH 4.0, (0.5 mg/mI, 200 i.d) at 37°C for
30 minutes with constant shaking. The color developed was
monitored at 405 nm using a Dynatec plate reader. Readings were
taken when the optical density of the maximum binding well
reached 1.5 (10 to 15 mm).
Culture of mesothelial cells
Human peritoneal mesothelial cells (HPMC) were isolated
from human omentum and cultured in Ham's F-12 medium
containing 10% FCS as previously described by us [16]. For
radiolabeling cells were seeded at a density of 2 X 105!cm2 in 75
cm2 tissue culture flasks (Falcon), incubated until confluent and
then labeled for 24 hours with fresh medium containing D-[6-3H]-
glucosamine hydrochloride (25 mCi/mi; sp.act. 20 Ci!mmol, Am-
ersham mt.). The medium was then removed and retained and the
cell layer washed with Ham's F-12 without serum or radioisotope,
the washings added to the medium and made 4 M with solid
guanidine HCI. The cell layer was extracted with 4% CHAPS/4 M
guanidine HCI as detailed by Kimura et al [17]. The extracts of the
cell layer (CL) and medium (CM) were analyzed by Sephadex
G-50 gel chromatography (12 ml bed volume equilibrated with
urea buffer comprising 8 M urea, 0.3 M NaC1, 20 mtvi Bis-Tris, pH
6.0, containing 0.5% (vol/vol) Triton X-100). The radiolabeled
macromolecules appeared in the void volume (V0) and were
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Fig. 3. Gel chromatography of HA extracted from (A) non-infected CAPD
fluid and (B) infected fluid. The HA extracted from each fluid was
processed as detailed in the Methods section and chromatographed on a
Sephacryl S-bOO column. The fractions were assayed for HA using the
ELISA protocol as described in the Methods.
quantified by scintillation spectroscopy. Labeled macromolecules
were concentrated on a DEAE-Sephacel (Pharmacia) anion
exchange column, eluted with 1.5 M NaC1, dialyzed against urea
buffer and then further analyzed by Mono-Q anion exchange
chromatography (Pharmacia). Samples were applied to a 2 ml
Mono-Q column and eluted with a linear gradient of NaCl in urea
buffer. Fractions (0.5 ml) were collected and analyzed for radio-
activity. The HA fractions, which eluted between 0.3 to 0.4 Nt NaCI
(Results section) were pooled and passed over an analytical
Sepharose CL-4B column (0.6 X 150 cm equilibrated in 4 M
guanidine, 50 m sodium acetate, pH 6.0, containing 0.5% Triton
X-100) before and after treatment with papain (0.075 U/mI;
Sigma) for 16 hours or Streptomyces hyaluronidase (50 mU/ml;
Sigma) for 16 hours.
Characterization of HA from CAPD fluid and non-labeled
mesothelial conditioned medium
CAPD fluid (two liters) or spent culture medium (one liter)
were centrifuged to remove cells and cell debris and passed over
a freshly prepared DEAE-Sephacel anion exchange column (0.5
x 5.0 cm) equilibrated in urea buffer. The column was washed
with urea buffer to remove unbound material, the bound material
eluted with 4 M guanidine HC1 (5 ml), dialyzed against urea buffer,
and then analyzed by Mono-Q anion-exchange as detailed above
for radiolabeled HA. The fractions eluting with 0.3 to 0.4 M NaCI
were pooled, dialyzed against water, lyophilized and treated with
papain (0.075 U/mI). The resultant material was made 4 M using
guanidine HC1 and chromatographed on an analytical Sephacryl
S-bOO column (0.6 X 150 cm). To confirm the presence of HA,
the samples of the papain treated material were further incubated
with hyaluronidase (50 mU/mi) before analysis by gel permeation
chromatography. In the above experiments each fraction was
dialyzed extensively against water, lyophilized and reconstituted in
PBS-Tween, and the HA content determined using the ELISA
assay for I-IA described above.
Statistics
Results are expressed as means SD and range as appropriate,
and compared using the Mann-Whitney U test.
Results
Hyaluronic acid levels in CAPD fluid
Prior to assay all samples were incubated with papain in the
absence of cysteine and EDTA. This served to digest proteogly-
cans, HA receptors, link protein and any other protein that bound
non-specifically to HA while the absence of cofactors ensured that
the HA present in the CAPD fluid was not fragmented [18]. After
such treatment the mean level of HA in non-infected four-hour
dwell fluid was 0.162 0.08 g/ml (N = 16). In contrast dialysate
obtained from patients with peritonitis after the same dwell time
had a concentration of 1.69 1.12 g/ml (N = 5), P < 0.0025.
Similarly, in non-infected overnight dwell (8 to 10 hr) fluid the
mean level of HA was 0.384 0.22 j.g/ml (N = 13), but infected
dialysate after the same dwell time had a mean concentration of
3.17 2.28 g/ml (N = 8), P < 0.0002. Figure 1. shows the
individual results from non-infected and infected dialysates.
The HA levels were also determined in fluid obtained from the
first washout from patients entering the CAPD program. The
levels (0.0032 0.0018 /Lg/ml; N = 7) were considerably lower
than those recorded above for established CAPD patients.
The most common invading organism isolated from the in-
fected CAPD fluid was Staph. epidermidis. We therefore investi-
gated whether this bacterium could account for the increased
levels of HA during peritonitis. Isolates were grown in nutrient
broth and then used to inoculate several samples of non-infected
CAPD fluid obtained after an overnight dwell. These were
incubated over night at 37°C, after which time the bacterial
number was greater than 106/ml. Analysis of the bacteria-free
supernatant indicated that the HA levels after incubation (mean
0.17 j.tg/ml; N = 3) did not show any increase over the original
CAPD samples (mean 0.17 .tg/ml; N = 3).
Next, longitudinal studies were carried out on fluids from four
patients in which the peritonitis had resolved with antibiotic
treatment and in one case of persistent infection. The results of
these experiments are included in Figure 2 and show that as the
infection resolved the levels of HA returned towards normal. In
contrast the levels remained high with persistent infection.
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Fig. 4. Anion-exchange liquid chromatography
on Mono-Q of [3H]-glucosamine-labeled
macromolecules extracted from human peritoneal
mesothelial cells (HPMC) secretions. The culture
medium was collected after 24 hours of labeling
and processed as described in the Methods
section. The salt gradient(----) was developed
using an fplc (Pharmacia) system. The fractions
marked with an horizontal bar were pooled for
further analysis (Fig. 5). Abbreviation is HA!
GP, hyaluronan/glycoprotein.
HA levels in serum
Serum levels of HA were measured in patients undergoing
CAPD and compared to those in normal controls. The mean level
for normals was 0.065 0,019 g/ml (N = 15). Patients without
peritonitis had a mean value of 0.21 0.074 Lg/ml (N = 16), and
in subjects with infection the mean value was 0.32 0.146 .tg/ml
(N = 8). This result was not significantly different from the
non-infected patients. In contrast the serum levels in all CAPD
patients without and with infection were both significantly higher
than normal controls (P < 0.0001 and 0,0001, respectively).
Characterization of HA from CAPD fluid
It has been reported that the cell biology of HA is related to the
size of its polysaccharide chain [19, 20]. Therefore it seemed
important to determine the Mr of I-IA present in both non-
infected and infected CAPD fluid. To achieve this I-IA together
with proteoglycans (PGs) and free glycosaminoglycan chains
(GAGs) from used dialysate were concentrated by passage over
DEAE-Sephacel, the HA separated from PGs and GAGs using a
Mono-Q anion-exchange column and analyzed on a dissociative
Sepharose S-1000 column. The gel chromatography elution pro-
files are shown in Figure 3, and are similar for HA extracted from
non-infected and infected fluid (compare Fig. 3a with Fig. 3b).
They also indicate that the HA isolated from both the non-
infected and infected CAPD fluid elutes as two high molecular
weight peaks (Kay 0.75 and 0.9). No small chain oligosaccharides
were detected in either peritoneal extract. Confirmation that we
were measuring solely HA and not proteoglycan was provided by
the absence of any effect of papain on the elution profiles together
with the marked shift to total volume following treatment with
hyaluronidase (data not shown).
Peritoneal mesothelial cells are a source of HA
To investigate the possible source of the HA in the CAPD fluid
human peritoneal mesothelial cells were cultured with [3H]-
glucosamine for 24 hours and the labeled macromolecules ex-
tracted from the culture medium (CM) and cell layer (CL). The
3H-labeled HA in the CM was separated from proteoglycans as
detailed above for CAPD fluid (Fig. 4). The HA pool was passed
over a dissociative Sepharose CL-4B column before and after
treatment with papain or papain and hyaluronidase (Fig. 5). The
elution profile indicate that the labeled material in the HA pool
was largely resistant to digestion with papain (compare Fig. 5 a
and b) but was totally degraded by treatment with a combination
of papain and hyaluronidase (compare Fig. 5 a and c). The labeled
material extracted from the cell layer was treated in an identical
manner. The results of these experiments indicated that perito-
neal mesothelial cells synthesize HA and that approximately 90%
of the total [3H1-labeled HA was located in the CM.
[3H}-labeled HA aliquots from the CM and CL were also
analyzed by gel chromatography filtration on Sephacryl-1000.
Figure 6 shows that the [3H]-labeled HA isolated from the CL was
eluted as a single broad peak (Kay 0.1 —0.3; Fig. 6b) whereas the
material isolated from the CM separated as a smaller population
having a Kay 0.6 to 0.85 (Fig. 6a). Thus the [3H]-labeled HA
present in the CM was of a molecular size similar to that
determined for material extracted from CAPD fluid (Fig. 3). In a
separate experiment the Mr of unlabeled HA extracted from the
spent medium from the culture of mesothelial cells was estimated
by gel chromatography and the distribution of the molecules in
the eluted fractions monitored with the HA ELISA assay. This
approach confirmed the molecular size for the mesothelial cell
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Fig. 5. Analysis of [3H1-hyaluronan synthesized by HPMC. A pooled
fraction was prepared as detailed in the legend to Fig. 4 and passed over
a dissociative Sepharose CL-4B column before (a) and after (b) treatment
with papain or (c) papain and hyaluronidase.
derived HA obtained by metabolic labeling with [3H]-glucosamine
(Fig. 7).
In a single experiment [3H]-glucosamine labeled HA was added
to samples of non-infected and infected effluent and its elution
profile determined before and after 16 hours of incubation at 37°C
as described above. There was no change in the hydrodynamic size
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Fig. 6. Sephaciyl S-bOO elutionprofiles of [3H]-labeled HA synthesized by
HPMC in culture. Cells were labeled with 3H]-glucosamine for 24 hours
and the labeled macromolecules extracted from the CM and CL were
processed on a Mono 0 column as detailed in Fig. 4 and the Methods
section. The HA fractions were pooled, incubated with papain and the
digestion products chromatographed on a Sephacryl S-1000 column. The
profiles show 3H-labeled HA isolated from (a) the CM and (b) the CL.
Each column was loaded with io dpm.
(data not shown) indicating that the HA had not undergone
digestion.
Discussion
By using a biotinylated Gi binding region derived from aggre-
can we have estimated the levels of HA in non-infected and
infected dialysate obtained from patients receiving CAPD as a
replacement therapy for end-stage renal failure. In addition we
have established that the peritoneal cell is a potential source of
HA. The results of our studies confirm the report by Lipkin et a!
[21] that non-infected CAPD effluent contains HA and further
demonstrates that its levels are significantly elevated in fluid taken
from patients with episodes of peritonitis. The raised levels in
these patients was not explained by products released from the
invading organism into the peritoneal cavity. Thus the results
0.4 0.6 0.8 1.0 1.2
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Fig. 7. Separation of HA synthesized by HMPC. HA was prepared from
pooled culture medium conditioned by HMPC as detailed for radiolabeled
HA in Fig. 6 and passed over a Sephacryl 5-1000 column. The fractions
were assayed for HA using the ELISA described in the Methods.
suggest that increased levels of HA in the peritoneum postinfec-
tion may represent an early event in the inflammatory response to
invading bacteria.
It is of interest that the level of HA in the initial wash out
following catheter insertion was significantly lower than in the
dialysate obtained from established CAPD. The dwell time of
these patients was much shorter (<1 hr). However, even had this
time been extended to four hours it is unlikely that a level of 0.162
jkglml would have been reached. This finding suggests that in
established CAPD patients the continual introduction of dialysate
fluid stimulates HA synthesis, possibly through the activation of
the peritoneal mesothelial cells. A similar phenomenon has been
described in respect of peritoneal macrophages from CAPD
subjects which are found to be more activated as compared to
those from normal individuals [22].
During peritonitis the clearance of macromolecules from the
blood to the dialysate is considerably enhanced [23]. However, the
serum levels of HA in the CAPD patients found by us are too low
to account for the increased concentrations in the fluid during
bacterial infection. Moreover, there was no significant increase
during active peritonitis. This together with the fact that non-
infected effluent had higher concentrations than the serum im-
plies that the majority of the HA was produced locally. The results
of our culture experiments strongly suggest that most if not all of
the peritoneal HA is derived from 'he mesothelial cell. The fact
that the Mr of the material produced by the cells in vitro is similar
to that found in vivo supports this hypothesis. The peritoneal
mesothelial cells in vitro synthesized HA, the majority of which
was released into the culturç medium by a mechanism that
probably involves partial depolymerization of the parent molecule
as judged by the higher Mr of the HA found in the cell layer. Once
released into the medium the molecule was stable and did not
appear to undergo any significant metabolism. Likewise, the HA
from either non-infected or infected dialysate was not further
modified by endoglycosidases present in CAPD fluid, as judged by
the absence of any change in the Mr of exogenous HA when
incubated in these dialysates.
The assay for HA also allowed us to monitor the isolation of
HA from CAPD fluid and thus obtain an estimate of its molecular
size. The HA characterized from both infected and non-infected
patients were clearly large molecules and there was no evidence of
low molecular weight products. This indicates that in the perito-
neum HA does not undergo depolymerization even during peri-
tonitis. This is an important finding since the ability of HA to
participate in regulatory processes is size dependent [19, 20].
Thus, digests of human umbilical HA but not the native molecule
nor its tetra- and hexasaccharides induce angiogenesis. Conse-
quently any cell biological role for HA in the peritoneum must be
ascribed to a high molecular form.
Our results for normal serum levels of HA are similar to those
of Engstrom-Laurent et al [24] who found values of 17 to 105
ng/ml in women and 13 to 75 nglml in men. We have confirmed
previous reports that serum concentrations are raised in renal
failure including patients receiving hemodialysis or CAPD [13—
15]. The exact mechanism for the elevation is uncertain though
decreased renal removal is possible.
The function of HA in the peritoneum and the consequences of
high levels in response to bacterial infection are at present
unknown. One explanation for the raised levels may be due to
impaired metabolism in the peritoneum as a result of infection.
HA in humans is mainly metabolized by the liver with the kidney
accounting for a minor amount. The presence of HA has been
demonstrated in several tissues and body fluids including serum,
synovial fluid lymph and broncho alveolar lavage fluid [25]. Its
levels are often elevated in these fluids in a number of diseases
and these high levels have been taken to indicate either increased
synthesis or impaired metabolism particularly by the liver but also
by the kidney. Hamura and co-workers [26] have shown that in an
experimental model of peritonitis HA levels accumulate and that
this event is in some way related to interleukin-1. Thus, a more
attractive explanation for the enhanced levels in fluid from CAPD
patients is an up-regulation of HA synthetase in the mesothelial
cells through the stimulation of these cells with cytokines or other
proinflammatory mediators released into the peritoneum during
peritonitis. There are several reports that co-culture of mesenchy-
mal cells including human pleural mesothelial cells with cytokines,
such as TGF-f3 and PDGF, up-regulate HA synthesis [8, 10, 27,
28]. In addition preliminary experiments in our laboratory have
shown that co-cultures of human peritoneal mesothelial cells with
peritoneal macrophage-conditioned medium increased HA syn-
thesis by the former cells, Our observations that peritoneal levels
of HA fell as the infection resolves and remained raised with
persistent peritonitis is compatible with this hypothesis. The exact
function of peritoneal HA is uncertain, but its increase with
inflammation suggests it could have a role in healing. Denudation
of mesothelium has been described in infection [29, 30] and the
augmented HA production may contribute to remodeling and
regeneration of the peritoneal lining.
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